Business Wire

RIX Industries and Element 1 Corporation Partner to Deploy Hydrogen Generators for Fuel Cell Propulsion Systems

8.10.2020 19:39:00 EEST | Business Wire | Press release

Share

RIX Industries (“RIX”), a leading developer of pneumatic energy technology, announced today that it has licensed proprietary methanol-based M-Series hydrogen generator technology from Element 1 Corp (e1). Under the terms of the license agreement, RIX has been granted rights to manufacture and deploy e1’s M-Series on-board hydrogen generators for use in fuel cell mobility applications, including marine vessels and off-road vehicles such as mining trucks, tractors, and heavy-lift trucks in both North America and Europe.

Governments across the globe are striving to reduce harmful emissions into the air and waterways. Tightening regulations combined with corporate sustainability initiatives are driving a massive migration to non-polluting electric propulsion systems, many of which utilize hydrogen fuel cells. RIX’s history of supporting the maritime industry, including the US Navy, together with e1’s methanol to hydrogen generator offers end-users an opportunity to adopt fuel cell motive solutions and work towards a zero-emissions future.

“RIX Industries has a global reputation for excellence and the addition of e1’s class-leading technology to our portfolio strategically aligns with our brand and our growth strategy,” said Bryan Reid, Chief Sales Officer at RIX. “We are focused on the clean energy future and firmly believe that there is a significant market opportunity that can be effectively addressed by RIX incorporating e1’s M-Series hydrogen generator into power solutions.”

Dr. David Edlund, e1 CEO, said, “e1 is delighted and privileged to be collaborating with RIX. They are a first-class manufacturing partner and a long-time authorized supplier to multiple branches of the U.S. military along with a wide range of commercial and industrial end-users. The on-board hydrogen generation technology being licensed to RIX is unique to e1 and is highly enabling to the mass commercialization of fuel cell systems for a wide variety of transportation-related fuel cell applications. I anticipate our relationship with RIX to broaden substantially over the not too distant future,” concluded Dr. Edlund.

The onboard storage of methanol used by e1’s hydrogen generators requires a fraction of the space on a maritime vessel as compared to compressed hydrogen, enabling a significantly greater range between fueling. This range extension is critical for not only marine vessels but also for heavy and medium-duty fuel cell trucks traveling long distances each day.

About RIX Industries:

Founded in 1878, RIX Industries is a technology-focused company, headquartered in Benicia, CA, specializing in the design, development and manufacture of pneumatic energy storage, transfer and control system solutions, including gas generation systems, precision compressor solutions and cryogenic cooling technologies for critical applications in Marine, Aerospace, Land, Energy, Industrial and Medical markets.

Visit www.CreateCompressCool.com for more information.

About Element 1 Corporation:

Element 1 designs and develops novel processes to enable the commercialization of clean-energy products and processes and alternative-energy technology. Through licensing our IP to strategic partners, our mission is to significantly reduce barriers to the adoption of hydrogen technology and fuel cells for a range of applications and to reduce the waste and pollution associated with flaring natural gas.

For more information about Element 1, please visit www.e1na.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Elizabeth Schroeder
Marketing Manager
RIX Industries
Phone: 707.745.7198
E-mail: eschroeder@rixindustries.com

Robert Schluter
President
Element 1 Corporation
Phone: 541.678.5943
E-mail: robert@e1na.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye